Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (5546)	1/24/2002 10:24:46 PM
From: rkrw	Respond to of 52153

<<<Arid actually had very little hype. >>> Yeah right... I guess you forgot that aria was calling themselves a genomics company. <<<They simply let their many papers speak for the company.>>> Wink, wink... with press releases.

To: scott_jiminez who wrote (5546)	1/25/2002 12:39:53 AM
From: RCMac	Read Replies (1) \| Respond to of 52153

Peter challenged you to name me another biotech that [like ARIA] went from $0.50 to $50 - that's a 100x rise from trough to peak, without much in the way of actual progress to justify a rise. You respond, with the spurious air that's it's a full answer during the same period: - AFFX: went from 8 to 150 [19X, not 100X] - CRA: went from 7 to 250 [36X, not 100X] - CRGN: went from 2 to 125 [62X, not 100X] - GENE: went from 5 to 80 [16X, not 100X] - GLGC: went from 3 to 150 [50X, not 100X] - HYSQ: went from 4 to 130 [32X, not 100X] and on and on and on…. [bracketed figures added] Seems like this proves Peter's point. It also suggests that you have some trouble judging what's hype and what isn't.